Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer

被引：10

作者：

Banerjee, S. ^{[1
]}

Grochot, R. ^{[2
]}

Shinde, R. ^{[3
]}

Lima, J. ^{[1
]}

Krebs, M. ^{[4
]}

Rahman, R. ^{[4
]}

Little, M. ^{[4
]}

Tunariu, N. ^{[5
]}

Curcean, A. ^{[2
]}

Badham, H. ^{[5
]}

Mahmud, M. ^{[6
]}

Turner, A. ^{[5
]}

Parmar, M. ^{[5
]}

Yap, C. ^{[7
]}

Minchom, A. ^{[2
]}

Lopez, J. ^{[2
]}

de Bono, J. ^{[2
]}

Banerji, U. ^{[2
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Gynaecol Unit, Sutton, Surrey, England

[2] Royal Marsden NHS Fdn Trust, Drug Dev Unit, Inst Canc Res, Sutton, Surrey, England

[3] Fiona Stanley Hosp, Med Oncol, Perth, ACT, Australia

[4] Christie NHS Fdn Trust, Expt Canc Med, Manchester, Lancs, England

[5] Royal Marsden NHS Fdn Trust, Inst Canc Research, Adult DDU ICR & RM, Clin Studies, Sutton, Surrey, England

[6] Inst Canc Res, Clin Trials & Stats Unit, Clin Studies, Sutton, Surrey, England

[7] Inst Canc Res, Clin Studies, Sutton, Surrey, England

来源：

关键词：

D O I：

10.1016/j.annonc.2021.08.1168

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

725MO

引用

页码：S728 / S728

页数：1